The treatment, called molnupiravir, is not recommended during pregnancy due to concerns over birth defects. Its use is limited compared with
The
Molnupiravir, greenlit by British regulators in November, has drawn attention as the world's first approved antiviral COVID-19 treatment which can be taken orally. The Japanese arm of Merck applied in early December for approval to produce and sell the drug in the country.
It is a medication that works by introducing "errors" into the virus' genetic code, thereby preventing the virus from further replication, according to the FDA. It is meant to be taken as soon as possible after a COVID-19 diagnosis and within five days of symptom onset.
Based on findings from animal studies, molnupiravir may cause fetal harm when administered to pregnant individuals. Both men and women capable of conception are advised to use birth control beyond the course of treatment, with women recommended to do so for four days after the final dose and men for at least three months after the last dose.
The treatment is not authorized for use in patients younger than 18 years of age because it may affect bone and cartilage growth, the FDA said.
Clinical trial data showed that molnupiravir reduced the risk of hospitalization or death by 30 percent.
Meanwhile,
People with diabetes or heart disease are among those considered to be at high risk of getting seriously ill from COVID-19.
==Kyodo
© Kyodo News International, Inc., source